GJB2 and KID syndrome: Mefloquine, an antimalarial drug, effectively blocks Cx50 and Cx36 GJ channels (Cruikshank et al., 2004) and showed promise in inhibiting KID syndrome-associated Cx26 mutations (Levit et al., 2015).